Advanced Enzyme Technologies Limited has informed the Exchange regarding Appointment of Mr Mukund Madhusudan Kabra as Executive Director of the company w.e.f. April 01, 2027.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies Limited's Board meeting on May 9, 2026 approved the annual audited consolidated financial results for FY 2025-26. Total revenue stood at ₹7,457.57 million (up 17% YoY) with net profit after tax of ₹1,736.08 million. The Board recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2), payable after shareholder approval at the 37th AGM, and deferred an interim dividend to preserve capital for potential strategic opportunities. Key board changes include the re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for another 5-year term from April 1, 2027, and the appointment of Mr. Pradip Bhailal Shah as Additional Director (Independent) effective June 12, 2026. Statutory auditors M S K A & Associates LLP were also reappointed for a second term of 5 years. Additionally, 49,350 equity shares were allotted under the ESOP Scheme 2022, increasing paid-up capital to ₹22,39,52,300.
The company's strong financial performance with 17% revenue growth and recommendation of dividend are positive signals for shareholders. The strategic capital preservation approach, while delaying interim dividend, indicates a focus on long-term value creation through potential M&A or corporate actions.